SAN FRANCISCO, Aug. 14 /PRNewswire-FirstCall/ -- Sirna
Therapeutics, Inc. (NASDAQ:RNAI) reported financial results today
for the quarter ended June 30, 2006. Sirna reported a net loss of
$10.1 million, or $0.15 per share in the second quarter of 2006,
compared to a net loss of $6.0 million, or $0.14 per share, for the
same period in 2005. Revenues for the second quarter of 2006 were
$0.9 million compared to $1.5 million for the same quarter in 2005.
Deferred revenues from collaboration partners, included on our
balance sheet at June 30, 2006, were $10.9 million. Operating
expenses were $11.7 million for the three months ended June 30,
2006 compared to $7.6 million for the same period in 2005.
Operating expenses for the second quarter of 2006 included $0.9
million of share-based employee compensation expense related to
Sirna's adoption of Statement of Financial Accounting Standards No.
123R as of January 1, 2006. Excluding the share-based employee
compensation expense, non-GAAP operating expenses for the second
quarter of 2006 were $10.8 million and the non-GAAP net loss was
$9.2 million or $0.14 per share. R&D expenses, excluding 123R
effects, were $6.9 million for the quarter ended June 30, 2006
compared to $4.8 million in the second quarter of 2005. Our
increase in R&D expenses reflects the advancement of the
Company's pipeline programs toward the clinic, the manufacturing of
Sirna-034 in preparation for Phase I clinical trials in hepatitis C
and the relocation of core scientific teams to our new research
center in San Francisco. G&A expenses, excluding 123R effects,
were $3.9 million for the quarter, compared to $1.6 million in the
second quarter of 2005. This increase in expenses is primarily due
to the additional business development and alliance management
activities necessary to establish and grow key corporate
partnerships, expansion of our intellectual property estate,
employee relocation expense, and Sarbanes-Oxley compliance. The
Company ended the second quarter with $92.2 million in cash, cash
equivalents and securities available for sale, which includes $47.4
million in net proceeds from the Company's follow-on offering
completed in May 2006 and $12.0 million in cash proceeds from our
partner GlaxoSmithKline as a result of the alliance entered into in
March 2006. With these additional financial resources, the company
is expanding its drug development activities and forecasts 2006
operating use of cash in the range of $30-$33 million. "With over
$92 million in financial resources at the end of the quarter, no
debt, and the potential for additional collaboration revenues, we
believe that we are in an excellent financial position to execute
on our strategy," said Howard W. Robin, Sirna President and CEO.
"In just a short period of time, we have established valuable
strategic collaborations with Allergan and GlaxoSmithKline, and we
are confident that we will have continued success in our strategy
of establishing increasingly valuable collaborations with companies
that are leaders in their fields." Recent Highlights * The Company
completed a secondary offering of 10.4 million shares at $5 per
share, and received total net proceeds of approximately $47.4
million. In addition, the Company received $12.0 million in
up-front payments from GlaxoSmithKline as part of its collaboration
in respiratory disease. * Sirna reported the final two month and
three month results from its recently completed Phase 1 trial on
Sirna-027, our RNAi-based drug for AMD which is partnered with
Allergan, Inc. Single ascending doses of Sirna-027 were safe and
well tolerated, and all 26 patients (100%) showed visual acuity
stabilization eight weeks after a single injection. In addition, at
the same time point, five of 26 patients (19%) experienced
clinically significant improvement in visual acuity, indicated by
an improvement of at least three lines on an eye chart. Twelve
weeks after a single injection, 24 of 26 patients (92%) showed
visual acuity stabilization, with four of 26 patients (15%)
experiencing clinically significant improvement in visual acuity.
Together with Allergan, we expect to initiate a Phase 2 study in
the second half of 2006. * Sirna is completing the enabling
toxicology studies on Sirna-034, our RNAi-based drug for hepatitis
C, and plans to file an IND with the FDA in the second half of this
year. The Company has started the manufacturing of Sirna-034 for
the Phase 1 clinical trial. * As part of our exclusive, multi-year
collaboration with GlaxoSmithKline (GSK) in respiratory diseases,
the companies initiated preclinical programs to develop RNAi-based
drugs for asthma and respiratory syncytial virus. * Three key
events occurred in the second quarter that solidify Sirna's
intellectual property position in the field of RNAi-based medicines
and drug delivery technologies: * In April, the U.S. Patent and
Trademark Office issued Sirna a patent covering any chemically
modified siRNA targeting I Kappa B kinase-gamma (IKK-gamma). This
is the first siRNA target patent issued in the United States and
sets an important precedent for Sirna's entire target patent
portfolio. Importantly, the claims of the patent cover any siRNA
sequence used against the gene and cover any type of chemical
modification or structure. * Sirna acquired the exclusive worldwide
license to the Zamore, et. al. microRNA patents from the University
of Massachusetts Medical School and the non-exclusive worldwide
license to the Tuschl, et. al. microRNA patents from New York's
Rockefeller University. Both licenses cover microRNA technology
(commonly known as antagomirs) crucial to the modulation of gene
expression. The combination of these licenses, together with
Sirna's existing microRNA patent portfolio, gives Sirna a leading
IP position in microRNAs. * Sirna's successful opposition led to
the European Patent Office (EPO) significantly limiting the scope
of the claims of the Kreutzer-Limmer patent, which is held by a
third-party patent holder. The claims have now been limited to
methods of making and using double stranded RNA with structures
that we believe are not commercially relevant to the discovery and
development of RNAi-based medicines. * Shares of Sirna Therapeutics
were added to the Russell 3000 Index and Russell 2000 Index,
effective June 30, 2006. Conference Call Information Sirna
Therapeutics President and CEO Howard W. Robin and his senior
management team will discuss progress to date in their clinical and
preclinical programs and provide an overview of financial results
during a conference call on Monday, August 14th at 4:30 p.m. EDT
(1:30 p.m. PDT). A live audio webcast of the call will be available
at the Company's corporate web site at http://www.sirna.com/.
Participants are urged to log on to the web site 15 minutes prior
to the scheduled start time to download and install any necessary
audio software. To access the live telephonic broadcast, domestic
callers should dial (877) 502-9273; international callers may dial
(913) 981-5582. An audio webcast replay will be available on
Sirna's web site, http://www.sirna.com/, for 14 days. Additionally,
a telephonic replay of the call will be maintained through Monday,
August 28, 2006. To access the replay, please dial (888) 203-1112
from the U.S. or (719) 457-0820 when calling internationally, using
confirmation code 1274601. About Sirna Therapeutics Sirna
Therapeutics is a clinical-stage biotechnology company developing
RNAi-based therapies for serious diseases and conditions, including
age-related macular degeneration (AMD), hepatitis C, dermatology,
asthma, respiratory syncytial virus (RSV) and Huntington's disease.
Sirna Therapeutics completed its Phase 1 clinical trial for
Sirna-027 in AMD in 2005 and with its strategic partner, Allergan,
Inc., will move Sirna-027 into Phase 2 clinical trials in the
second half of 2006. Sirna has selected a clinical candidate for
hepatitis C virus, Sirna-034, which the Company plans to bring into
Phase 1 clinical trials by the end of 2006. Sirna has established
an exclusive multi-year strategic alliance with GlaxoSmithKline for
the development of siRNA compounds for the treatment of respiratory
diseases. Sirna has a leading intellectual property portfolio in
RNAi covering over 250 mammalian gene and viral targets and over
200 issued or pending patents covering other major aspects of RNAi
technology, including the microRNA technology. More information on
Sirna Therapeutics is available on the Company's web site at
http://www.sirna.com/ . Safe Harbor Statement Statements in this
press release which are not strictly historical are
"forward-looking" statements which should be considered as subject
to many risks and uncertainties. For example, most drug candidates
do not become approved drugs. The development of Sirna-027 and
Sirna-034 as well as Sirna's other programs are still at a
relatively early stage. All of these programs, and Sirna's ability
to obtain milestone and royalty payments for them, are subject to
significant risks and unknowns, are highly contingent upon future
successes, and require significant funding. In addition, patent
applications may not result in issued patents, and issued patents
may not be enforceable or could be invalidated. Other risks and
uncertainties include, among others, Sirna's early stage of
development, Sirna's history and expectation of losses and need to
raise capital, Sirna's need to obtain clinical validation and
regulatory approval for Sirna-027, Sirna-034 and Sirna's other
product candidates, any of which could have negative results,
Sirna's need to engage collaborators, Sirna's need to obtain and
protect intellectual property, and the risk of third-party patent
infringement claims. These and additional risk factors are
identified in Sirna's Securities and Exchange Commission filings,
including Forms 10-K and 10-Q and in other SEC filings. Sirna
undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may
arise after the date of this release. Contacts: Stephan Herrera
Executive Director, Investor Relations Sirna Therapeutics, Inc.
415.281.2704 Brandon Belcher The Ruth Group 646.536.7009 SIRNA
THERAPEUTICS, INC. CONDENSED BALANCE SHEETS (In thousands) June 30,
December 31, 2006 2005 (Unaudited) (Note 1) ASSETS Cash, cash
equivalents and securities available for sale $92,177 $45,692
Property and equipment, net 2,954 1,906 Other assets, net 3,482
1,919 $98,613 $49,517 LIABILITIES AND STOCKHOLDERS' EQUITY Current
liabilities $10,618 $6,699 Deferred revenue, long-term 6,865 2,917
Other long-term liabilities 264 275 Stockholders' equity 80,866
39,626 $98,613 $49,517 Note 1. Derived from audited financial
statements. SIRNA THERAPEUTICS, INC. CONDENSED STATEMENTS OF
OPERATIONS (Unaudited, in thousands, except for per share amounts)
Three Months Ended Six Months Ended June 30, June 30, 2006 2005
2006 2005 Revenues: Contract revenue $852 $51 $1,278 $94 Contract
manufacturing revenue -- 1,477 -- 1,942 Total revenues 852 1,528
1,278 2,036 Operating expenses: Cost of contract manufacturing --
1,264 -- 1,658 Research and development 7,186 4,780 12,826 10,884
General and administrative 4,493 1,550 7,874 3,720 Total operating
expenses 11,679 7,594 20,700 16,262 Loss from operations (10,827)
(6,066) (19,422) (14,226) Interest and other income 753 116 1,370
291 Interest expense -- -- -- (25) Net loss $(10,074) $(5,950)
$(18,052) $(13,960) Net loss per common share, basic and diluted
$(0.15) $(0.14) $(0.29) $(0.34) Weighted average common shares
outstanding, basic and diluted 66,126 41,577 63,129 41,527
DATASOURCE: Sirna Therapeutics, Inc. CONTACT: Stephan Herrera,
Executive Director, Investor Relations of Sirna Therapeutics, Inc.,
+1-415-281-2704; or Brandon Belcher of The Ruth Group,
+1-646-536-7009, for Sirna Therapeutics, Inc. Web site:
http://www.sirna.com/
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Sep 2023 to Sep 2024